3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Conditions
Melanoma
2
Carcinoma, Basal Cell
1
Interventions
pembrolizumab
54
Nivolumab
50
Ipilimumab
28
Cyclophosphamide
16
binimetinib
10
Specimen Handling
10
Magnetic Resonance Spectroscopy
10
fludarabine
9
Radiosurgery
9
relatlimab
8
encorafenib
8
Opdualag
8
Biopsy
8
aldesleukin
7
Interleukin-2
7
atezolizumab
6
Immunotherapy
6
Blood Specimen Collection
6
cemiplimab
5
CTLA-4 Antigen
5
Bevacizumab
5
trametinib
4
fludarabine phosphate
4
dabrafenib
4
Temozolomide
4
Paclitaxel
4
Immune Checkpoint Inhibitors
4
spartalizumab
3
Surgical Procedures, Operative
3
Metformin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Melanoma
×
daromun
×
Clear all
NCT03567889
2025-12-17
NeoDREAM
Philogen S.p.A.
Phase 3
Recruiting
186 enrolled
NCT06284590
2024-10-26
INTACT/MeRCI
Philogen S.p.A.
Phase 2
Recruiting
162 enrolled